Biomind Labs Inc.
BMND
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 718.45% | -85.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 718.45% | -85.47% | |||
| Operating Income | -718.45% | 85.47% | |||
| Income Before Tax | -555.62% | 81.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -555.62% | 81.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -555.62% | 81.55% | |||
| EBIT | -718.45% | 85.47% | |||
| EBITDA | -722.84% | 85.56% | |||
| EPS Basic | -576.92% | 82.19% | |||
| Normalized Basic EPS | -587.50% | 82.22% | |||
| EPS Diluted | -576.92% | 82.19% | |||
| Normalized Diluted EPS | -587.50% | 82.22% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||